Healius (HLS.AX) Stock Price
Healius Price
Over the last 19 years Healius grew revenue by 8.9% annually, reaching 1.37 B AUD. Earnings per share have grown at 6.9% per year over the last 15 years. For Healius, the net margin of -30.3% is down versus 13.5% a few years ago. At today's price the dividend yield works out to roughly 1.51%. The consensus 12-month price target for Healius is 0.77 AUD, about 96.2% above where the stock trades today. Of 15 analysts, 1 rate the stock a buy — an overall Sell consensus.
Healius stock price
Healius business model & stock analysis
Frequently asked questions about Healius
Healius Ltd is a leading healthcare company based in Australia. The company's business model revolves around delivering exceptional healthcare services and solutions. Healius operates a diverse range of medical centers, pathology laboratories, and imaging clinics throughout the country. With a focus on patient care and innovation, Healius aims to provide accessible and high-quality healthcare to individuals and communities. The company's comprehensive range of services includes general practitioner consultations, pathology testing, radiology imaging, and specialty healthcare options. Healius' business model centers on delivering efficient, integrated, and patient-centric healthcare solutions, making it a prominent player in the Australian healthcare industry.
Healius Ltd is primarily active in the healthcare industry.
The main competitors of Healius Ltd in the market include companies such as Sonic Healthcare, Primary Health Care, and Ramsay Health Care.
Healius Ltd, formerly known as Primary Health Care Ltd, is a leading Australian healthcare company. Established in 1985, Healius has a rich history of providing quality healthcare services to patients nationwide. Over the years, the company has evolved and expanded its offerings, including medical centers, pathology services, and diagnostic imaging. With a network of over 2,000 doctors and healthcare professionals, Healius focuses on delivering patient-centric care and innovative solutions. The company's commitment to excellence has made it a trusted name in the healthcare industry, providing comprehensive and accessible medical services to individuals and communities across Australia.
Healius Ltd has achieved significant milestones over the years. Some notable achievements include expanding its network of medical centers, introducing innovative healthcare services, and forging strategic partnerships. The company has also demonstrated consistent financial growth, delivering strong revenue and earnings results. Furthermore, Healius Ltd has focused on enhancing patient experiences and improving healthcare outcomes through technological advancements and process improvements. With its commitment to excellence, Healius Ltd continues to make strides in the healthcare industry, solidifying its position as a leading provider of integrated healthcare services.
Healius Ltd is primarily present in Australia.
Healius Ltd represents values of integrity, excellence, collaboration, and compassion. The company is committed to delivering high-quality healthcare services to its patients, fostering a culture of trust and accountability. With a focus on innovation and patient-centered care, Healius aims to provide accessible and efficient healthcare solutions. As a leading healthcare company in Australia, Healius embraces a corporate philosophy centered around continuously improving patient outcomes, investing in advanced technologies, and maintaining strong ethical standards. With its dedicated and skilled team, Healius is devoted to making a positive difference in people's lives through its diversified range of services and commitment to quality healthcare delivery.
Analysts currently set an average price target of 0.75 AUD for the Healius stock (median: 0.77 AUD), implying +92.7 % versus the latest price. The consensus is based on 15 analyst ratings.
15 analysts currently rate the Healius stock: 0 recommend buying, 7 holding and 8 selling.
Converted at the current exchange rate, the Healius share trades at 0.24 EUR (0.39 AUD).
The Healius share (HLS.AX) is listed on 4 stock exchanges, including: SIX (Zürich) (PGZ.SW), ASX (HLS.AX), Frankfurt (PGZ.F), Düsseldorf (PGZ.DU).
Healius Ltd is an Australian company that offers a comprehensive portfolio of healthcare services. It is a leading provider of integrated medical services, focusing on medical imaging, pathology, radiology, telemedicine, and general medicine. The company was founded in 2018 and is headquartered in Sydney, Australia. The following describes Healius Ltd's business model in more detail, as well as the various divisions and products the company offers. Business model: Healius Ltd specializes in integrated medical services. The company offers a wide range of products and services at medical locations in Australia to ensure optimal customer satisfaction. The advantage of this business model is that it provides a broad customer base and the opportunity to offer various services to generate revenue. Divisions: Healius Ltd offers a range of specialties including medical imaging, pathology, radiology, telemedicine, and general medicine. It is a leading provider of integrated medical services in Australia. The company performs medical diagnostic tests and provides consulting services to ensure quick diagnosis and proper treatment for its customers. Products: Medical imaging and radiology are the core competencies of Healius Ltd. The company has state-of-the-art technology for performing X-rays, CT scans, MRIs, ultrasound examinations, etc. Moreover, the company offers pathology services for disease diagnosis and medical tests to enable accurate medical diagnoses. Telemedicine is another important service provided by Healius Ltd. The company offers virtual doctor consultations, allowing customers to address their health issues from the comfort of their homes. The company also provides an online service for patients to access their medical history. In summary, Healius Ltd is a leading provider of medical services in Australia, offering a wide range of products and services to ensure optimal customer satisfaction. The company has a strong presence in various specialties such as medical imaging, pathology, radiology, telemedicine, and general medicine. The company has strong growth potential as it has a broad customer base and offers a comprehensive portfolio of services and products to generate revenue.
The revenue of Healius is 1.37 B AUD. This figure is based on current financial data and reflects the company's business performance.
The profit of Healius is -415.60 M AUD. The net profit reflects the company's profitability after deducting all expenses.
The price-to-earnings ratio (P/E) of Healius is currently -0.68. The P/E ratio compares the current share price to the earnings per share and helps investors assess the valuation of the Healius stock.
The price-to-sales ratio (P/S) of Healius is currently 0.21. The P/S ratio compares the market capitalization to the annual revenue and serves as a valuation metric for the Healius stock.
The Eulerpool Quality Score for Healius is 0/10.
The ISIN of Healius is AU0000033359. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.
The WKN of Healius is A2PAL9. The WKN (Wertpapierkennnummer) is a six-digit German security identification number.
The ticker of Healius is HLS.AX. The ticker symbol is used to trade Healius shares on the stock exchange.
Healius stock
Healius Peer Group
Healius Ticker
Healius FIGI
All fundamentals and in-depth analysis of Healius
Our stock analysis for Healius stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Healius. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.